Monte Rosa Therapeutics, Inc. GLUE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$44.5M-195% | -$46.14M— | -$27.08M-13.5% | -$12.3M+59.4% | $46.89M+247% | ||
| $2.03M-0.9% | $2.09M+1.3% | $2.1M-0.4% | $2.13M+3.2% | $2.05M+8.0% | ||
| $5.95M+12.3% | $4.31M-3.6% | $4.36M+1.9% | $4.89M+8.7% | $5.3M+8.7% | ||
| $0-100% | —— | —— | —— | $59K— | ||
| $4.38M+140% | -$10.61M-180% | —— | -$1.1M-380% | -$10.87M-114% | ||
| -$3.71M-42.4% | $8.74M+136% | $4.19M+80.1% | -$2.47M-221% | -$2.61M+32.9% | ||
| $2.92M+72,925% | -$1.38M— | -$941K-137% | $1.71M+1,267% | $4K-99.8% | ||
| -$4.21M+95.0% | $4.22M-95.3% | $110.22M+1,296% | -$22.97M-634% | -$83.94M-7,789% | ||
| -$434K-53.4% | -$298K+33.9% | -$354K-174% | -$144K+51.5% | -$283K+39.9% | ||
| $9K-99.3% | $0+100% | $2.6M+1,151% | $961K+194% | $1.24M+12,250% | ||
| -$37.37M+17.9% | -$43.01M-133% | $100.43M+578% | -$34.72M-25.0% | -$45.49M-19.2% | ||
| $1.87M+17.7% | $767K+319% | $651K+63.2% | $1.7M-16.2% | $1.59M+14.7% | ||
| -$261M-160% | -$65.07M-111% | —— | —— | -$100.23M-1,117% | ||
| $4.52M+32,200% | $5.72M+4,791% | $0— | -$14K-102% | $14K-94.3% | ||
| —— | $357K+123% | $0-100% | —— | —— | ||
| $328.34M+2,345,150% | $29.62M+4,772% | $348K+2,220% | $365K-99.6% | $14K-94.3% | ||
| $29.97M+121% | -$78.46M-180% | —— | -$9.03M— | -$145.71M-419% | ||
| $2.03M-0.9% | $2.09M+1.3% | $2.1M-0.4% | $2.13M+3.2% | $2.05M+8.0% | ||
| -$3.71M-42.4% | $8.74M+136% | $4.19M+80.1% | -$2.47M-221% | -$2.61M+32.9% | ||
| -$7M— | —— | —— | —— | $0— | ||
| -$4.21M+95.0% | $4.22M-95.3% | $110.22M+1,296% | -$22.97M-634% | -$83.94M-7,789% | ||
| -$434K-53.4% | -$298K+33.9% | -$354K-174% | -$144K+51.5% | -$283K+39.9% | ||
| $9K-99.3% | $0+100% | $2.6M+1,151% | $961K+194% | $1.24M+12,250% | ||
| $2.92M+72,925% | -$1.38M— | -$941K-137% | $1.71M+1,267% | $4K-99.8% | ||
| —— | $1.75M— | $1.75M— | $1.75M— | $1.75M— | ||
| $487K— | —— | —— | —— | $0— | ||
| $324.3M— | —— | —— | —— | $0— | ||
| $2.74M+800% | —— | —— | $146K— | $304K-69.1% | ||
| -$49K+84.0% | —— | -$235K+4.5% | -$650K— | -$307K-379% | ||
| -$434K-53.4% | -$298K+33.9% | -$354K-174% | -$144K+51.5% | -$283K+39.9% | ||
| —— | $0-100% | $0-100% | —— | —— | ||
| -$39.24M+16.7% | -$43.78M-134% | $99.78M+566% | -$36.42M-22.2% | -$47.08M-19.0% | ||
| -$39.24M+16.7% | -$43.78M-134% | $99.78M+566% | -$36.42M-22.2% | -$47.08M-19.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Monte Rosa Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.